FEB 27, 2019 1:30 PM PST

Comprehensive NTRK Fusion Detection, Agnostic of the Fusion Partner, for Optimal Identification of Rare Genomic Events Using TruSightTM Oncology 500

Presented at: Drug Discovery 2019
Sponsored by: Illumina
Speakers

Abstract

NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events and in the future may enables the use of emerging treatments such as NTRK inhibitors. NTRK genes include numerous potential fusion partners, large intronic regions and G-C rich content, making accurate and comprehensive detection of NTRK fusions difficult to perform in the lab. Amongst the variable performance of NTRK fusion assays, NTRK detection from RNA using Hybrid-Capture NGS provides comprehensive and accurate fusion detection, agnostic of the fusion partner. TruSightTM Oncology 500 is the latest comprehensive genomic profiling assay from Illumina and enables optimal NTRK fusion detection. 

Learning Objectives:

1. Value to adopt comprehensive genomic profiling in today's oncology care.
2. How the Illumina TruSightTM Oncology 500 comprehensive genomic profiling assay enables optimal NTRK fusion detection. 


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
NOV 17, 2021 8:00 AM PST
C.E. CREDITS
NOV 17, 2021 8:00 AM PST
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
FEB 27, 2019 1:30 PM PST

Comprehensive NTRK Fusion Detection, Agnostic of the Fusion Partner, for Optimal Identification of Rare Genomic Events Using TruSightTM Oncology 500

Presented at: Drug Discovery 2019
Sponsored by: Illumina

Specialty

Cancer Research

Dna Sequencing

Oncology

Genomics

Cancer Therapeutics

Molecular Diagnostics

Genetics

Clinical Diagnostics

Biomarkers

Clinical Oncology

Cancer Diagnostics

Bioinformatics

Molecular Biology

Immunology

Gene Sequencing

Geography

North America71%

Asia7%

Registration Source

Website Visitors100%

Job Title

Medical Laboratory Technician36%

Consultant27%

Executive18%

Marketing/Sales18%

Organization

Biotech Company29%

Pharmaceutical Company14%

Manufacturer - Other14%

Manufacturer & Biotech/pharma7%

Medical Device Company7%

Independent Laboratories7%


Show Resources
Loading Comments...
Show Resources